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Dose Ratios between High Dose Oral Morphine or Equivalents and Oral 
Methadone 
Abstract 
Background: Methadone is a commonly used opioid in hospice and palliative care for patients with 
refractory pain. Various methadone dose conversion methods utilize progressively higher morphine 
equivalent dose (MED) to methadone dose ratios to compensate for increased methadone potency with 
escalating opioid doses. 
Objective: The purpose of this study was to determine the dose ratio between equianalgesic doses of 
high dose oral morphine (daily doses >1200 mg morphine or MED) and oral methadone. 
Methods: This study was a retrospective chart review of 324 patients who received methadone at Strong 
Memorial Hospital or the associated outpatient clinic during a nine-month period in 2011. Ten patients 
met the study inclusion and exclusion criteria. A Wilcoxon signed-rank test was used to compare the pain 
scale scores. The Spearman correlation coefficient was used to assess level of correlation between 
morphine dose and methadone dose. 
Results: Patients rotated to methadone from high opioid doses had a two-point improvement in median 
pain scale scores after conversion (p=0.039). However, there was no correlation identified for patients 
taking daily doses >1200 mg oral morphine or MED prior to methadone rotation (p=0.19). There were no 
reported methadone adverse effects during the study. 
Conclusions: No correlation was identified between high MED doses and methadone at dose stabilization 
after opioid rotation. A fixed maximum methadone dose of 30 mg/day produced clinically meaningful 
improvements in pain scores without adverse drug effects. Caution should be exercised before 
considering rotation to methadone doses higher than 30 mg/day in a patient receiving >1200 mg oral 
MED/day. 
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Abstract 
 
Background: Methadone is a commonly used opioid in hospice and palliative care for patients 
with refractory pain.  Various methadone dose conversion methods utilize progressively higher 
morphine equivalent dose (MED) to methadone dose ratios to compensate for increased 
methadone potency with escalating opioid doses.   
 
Objective:  The purpose of this study was to determine the dose ratio between equianalgesic 
doses of high dose oral morphine (daily doses >1200mg morphine or MED) and oral methadone.  
 
Methods: This study was a retrospective chart review of 324 patients who received methadone at 
Strong Memorial Hospital or the associated outpatient clinic during a 9-month period in 2011. 
Ten patients meet the study inclusion and exclusion criteria.  A Wilcoxon signed rank test was 
used to compare the pain scale scores. The Spearman correlation coefficient was used to assess 
level of correlation between morphine dose and methadone dose.  
 
Results: Patients rotated to methadone from high opioid doses had a 2-point improvement in 
median pain scale scores after conversion (p=0.039). However, there was no correlation 
identified for patients taking daily doses >1200 mg oral morphine or MED prior to methadone 
rotation (p=0.19).  There were no reported methadone adverse effects during the study. 
 
Conclusions: No correlation was identified between high MED doses and methadone at dose 
stabilization after opioid rotation. A fixed maximum methadone dose of 30mg/day produced 
clinically meaningful improvements in pain scores without adverse drug effects. Caution should 
be exercised before considering rotation to methadone doses higher than 30mg/day in patient 
receiving >1200mg oral MED/day. 
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Introduction 
 
Methadone is a unique opioid that is a delta and mu opioid receptor agonist, N-methyl-D-
aspartate (NMDA) receptor antagonist, and inhibits reuptake of serotonin and norepinephrine.1-4  
It is metabolized via N-demethylation by CYP 3A4, 2B6, 2C8, 2C9, 2C19, and 2D6 to the 
inactive metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenypyrrolidine (EDDP) which is 
eliminated in the feces and urine.5   
Methadone is commonly used in hospice and palliative care for patients with refractory pain 
despite aggressive opioid titration, neuropathic pain, renal failure, morphine allergy, opioid-
induced adverse effects, and dysphagia who require long-acting opioids.6 Methadone is 
particularly efficacious for opioid rotation in patients with intolerable opioid induced adverse 
effects such as myoclonus, opioid-induced hyperalgesia (OIH), hallucinations, sedation, and 
seizures, or uncontrolled pain. This is attributed to its increased potency with prior exposure to 
high opioid doses.7   Potential reasons for potency differences include incomplete cross-tolerance 
between other mu opioid receptor agonists and methadone causing changes in receptor binding 
affinities, reverse opioid tolerance from NMDA receptor antagonism, and elimination of opioid 
active metabolites such as morphine-3-glucuronide (M-3-G) and hydromorphone-3-glucuronide 
(H-3-G).   
Various methadone dose conversion methods utilize progressively higher morphine equivalent 
dose (MED) to methadone dose ratios to compensate for increased methadone potency with 
escalating opioid doses although variations exist among dose range cut-offs.8-15 While there are 
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many conversion models available, the existing evidence does not support the accuracy of one 
model over another.   Previous methadone conversion studies included small numbers of patients 
on oral MED > 1200mg/day, but to our knowledge no studies have focused exclusively on this 
patient population.16-23 At our own institution, we use the American Academy of Hospice and 
Palliative Medicine (AAHPM) equianalgesic table as a guide, however, there is no guidance for 
MED > 1200mg/day.15  Our clinical experience suggests that a more conservative oral MED to 
oral methadone dose ratio is needed for patients receiving these higher oral MEDs.  Thus, the 
primary objective of this study was to determine the dose ratio between equianalgesic doses of 
high dose oral morphine (daily doses >1200mg morphine or MED) and oral methadone.  
 
Methods  
 
Sample 
 
We retrospectively reviewed the electronic medical records of 324 patients who received 
methadone while at Strong Memorial Hospital or the associated Palliative Care Clinic from 
March 1 through December 31, 2011. Patients were eligible for study inclusion if they were > 18 
years and taking high dose oral morphine or MED, defined as > 1200mg/day at the time of 
methadone rotation. Exclusion criteria included incomplete medical records or lack of a 
documented pain scale score prior to and post methadone rotation. Patients receiving methadone 
prior to the start of the study period were also excluded. Data were collected from an electronic 
medical record database. This study was approved by the University of Rochester Research 
Subjects Review Board. 
 
Measurements 
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Pain was assessed on a 0-10 scale with 0 designating “no pain” and 10 indicating the “worst 
possible pain.” We collected the median pain scale score on the day prior to methadone rotation 
and at dose stabilization. A methadone dose was considered stabilized when the patient required 
no dose modifications for 5 consecutive days. .  If patient was discharged from hospital earlier 
than day 5 of methadone therapy, the dose on the day of discharge was used. To determine a 
morphine to methadone ratio, the daily oral morphine or MED prior to methadone rotation and 
the methadone dose after stabilization were collected. Adverse events and reason to discontinue 
methadone were also collected.  
 
Data analysis 
 
Wilcoxon signed rank test was used to compare the median pre-rotation and post-rotation pain 
scale scores. The Spearman correlation coefficient was used to assess level of correlation 
between previous morphine dose or MED and stabilized methadone dose.  
 
Results 
 
Baseline characteristics 
Of 324 patients, 10 met inclusion criteria. Baseline characteristics are presented in Table 1. The 
average age was 51 years and most patients (n=7) were male. The underlying diagnosis related to 
pain was malignancy in all cases. 
 
Reason for methadone rotation 
 Seven patients were transitioned off of a hydromorphone infusion to methadone for ease of 
opioid administration upon hospital discharge. Three patients required methadone rotation due to 
inadequate analgesia from high dose opioids and one patient experienced over-sedation from 
hydromorphone. 
Change in pain scale 
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Pain was assessed by a nurse at least every 2 hours in most patients.  Table 2 compares median 
pain scale scores (MPSS) and methadone dose regimens before and after opioid rotation. Seven 
of the 10 patients experienced improved pain control after switching to methadone. Two patients 
had no change in MPSS and one had higher pain scale scores after switching to methadone. The 
patient with increased pain scores was later titrated to a higher methadone dose with improved 
pain control, but not within the specified 5 day dose stabilization time frame. The titrated 
methadone dose for this patient was determined based on the patient’s as needed short-acting 
opioid use.   The Wilcoxon signed rank test showed a median difference of 2 points on the 0-10 
pain scale (p=0.039). 
 
Dose ratio 
 
There was no correlation between previous oral morphine dose or MED and stabilized 
methadone dose (p=0.19), as seen in Figure 1. Most patients were started on 30mg of 
methadone/day (divided every 8 hours) and the majority of patients (n=8) were stabilized on this 
dose. Of the two patients who required higher than 30mg/day of methadone, one patient did not 
report a difference on the pain scale and the other patient reported worsened pain after 
methadone rotation. 
 
Adverse events and discontinuation 
Methadone was well tolerated in all study patients. There were no reported adverse drug effects 
during the specified study period. Methadone was not discontinued in any patients. 
 
Discussion 
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This study further elucidates the underestimated potency of methadone in patients with prior 
opioid exposure. If the palliative care providers followed the AAHPM dosing card 
recommendations exactly, the study patients potentially could have been converted to methadone 
doses exceeding 60mg/day. Based on the palliative care providers’ clinical experience and 
concern about methadone drug accumulation, they utilize a more conservative conversion 
strategy that rarely exceeds 30mg/day. Clinically meaningful improvements in median pain 
scores of 2 points on the 0-10 pain scale was noted indicating adequate pain control in the 
majority of patients with a fixed maximum methadone dose of 30mg/day. No adverse drug 
effects were observed during the study period.  These outcomes support a more conservative 
approach to methadone rotation in patients with high dose opioid exposure.  Although we were 
not able to determine a specific fixed dose ratio between MED and methadone for high dose 
opioids, the results of our study are consistent with prior studies examining this relationship.17 
One of our patients was taking >10,000mg MED/day and another was taking only 1200 mg, but 
both achieved adequate pain control on a fixed maximum methadone dose, suggesting only 
partial cross-tolerance exists between opioids and methadone . Beyond the threshold of 1200mg 
MED/day, the cross tolerance between opioids and methadone appears to become very low, as 
seen in the increasingly large MED to methadone ratios found. This resulted in a potentially 
predictable methadone dose plateau for these patients with relatively high MED requirements 
and supports the safety and efficacy of a fixed maximum dose. 
There are several limitations of our study. It included a small sample size of patients from one 
medical center. Given the retrospective nature of the study, data collection relied on electronic 
records which could potentially contain inaccurate opioid dosing documentation especially 
regarding as needed patient controlled analgesia use. We did not collect certain patient specific 
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factors, such as drug interactions that may have had an effect on methadone metabolism and 
dosing regimens. Lastly, our providers utilize a very conservative methadone rotation approach 
in all palliative care patients based on their clinical experience which may have confounded our 
results. 
 
Conclusions 
This study is a retrospective chart review of opioid conversions from a high oral MED > 
1200mg/day to oral methadone.  No correlation was identified between high MED doses and 
methadone at dose stabilization after opioid rotation. A fixed maximum methadone dose of 
30mg/day produced clinically meaningful improvements in pain scores without adverse drug 
effects. Caution should be exercised before considering rotation to methadone doses higher than 
30mg/day in patient receiving >1200mg oral MED/day.  
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